Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

405 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study).
LeCaer H, Barlesi F, Corre R, Jullian H, Bota S, Falchero L, Vergnenegre A, Dujon C, Delhoume JY, Chouaid C; GFPC 0504 Team. LeCaer H, et al. Among authors: chouaid c. Br J Cancer. 2011 Oct 11;105(8):1123-30. doi: 10.1038/bjc.2011.331. Epub 2011 Sep 20. Br J Cancer. 2011. PMID: 21934690 Free PMC article. Clinical Trial.
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Girard N, et al. Among authors: chouaid c. J Thorac Oncol. 2023 Feb;18(2):181-193. doi: 10.1016/j.jtho.2022.10.003. Epub 2022 Oct 25. J Thorac Oncol. 2023. PMID: 36307040 Free article.
Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study.
Benderra MA, Serrano AG, Paillaud E, Tapia CM, Cudennec T, Chouaïd C, Lorisson E, de la Taille A, Laurent M, Brain E, Bringuier M, Gligorov J, Caillet P, Canoui-Poitrïne F. Benderra MA, et al. Among authors: chouaid c. ESMO Open. 2023 Oct;8(5):101831. doi: 10.1016/j.esmoop.2023.101831. Epub 2023 Oct 11. ESMO Open. 2023. PMID: 37832389 Free PMC article.
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.
Macro M, Hulin C, Vincent L, Charvet-Rumpler A, Benboubker L, Calmettes C, Stoppa AM, Laribi K, Clement-Filliatre L, Zerazhi H, Honeyman F, Richez V, Maloisel F, Karlin L, Barrak J, Chouaid C, Leleu X. Macro M, et al. Among authors: chouaid c. Ann Hematol. 2023 Aug;102(8):2137-2151. doi: 10.1007/s00277-023-05278-3. Epub 2023 Jun 10. Ann Hematol. 2023. PMID: 37301786 Free PMC article.
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He K, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S; SAPPHIRE Investigators. Borghaei H, et al. Ann Oncol. 2024 Jan;35(1):66-76. doi: 10.1016/j.annonc.2023.10.004. Epub 2023 Oct 20. Ann Oncol. 2024. PMID: 37866811 Clinical Trial.
405 results